Business Context and Reporting Period
This Form 8-K was filed by Rein Therapeutics, Inc. (formerly Aileron Therapeutics, Inc.) on January 10, 2025. The report details a corporate name change and the associated amendment to the company's governing documents.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- Corporate Name: The company changed its name from "Aileron Therapeutics, Inc." to "Rein Therapeutics, Inc." effective at 4:00 p.m. Eastern Time on January 10, 2025.
- Governing Documents: The Restated Certificate of Incorporation and Amended and Restated Bylaws were amended solely to reflect the new name.
- Stockholder Rights: The name change does not affect the rights of the company's stockholders.
Guidance, Outlook, and Other Events
- New Trading Symbol: The new trading symbol for the company's common stock on The Nasdaq Capital Market is "RNTX".
- Trading Commencement: Trading under the new name and symbol is expected to commence on January 13, 2025.
- CUSIP Number: The CUSIP number for the common stock will remain unchanged.
- Risks and Contingencies: No specific risks, contingencies, or unusual items were disclosed in this filing.
Investor Verification Checklist
- Verify the new ticker symbol "RNTX" on trading platforms starting January 13, 2025.
- Confirm that existing holdings under the former name "Aileron Therapeutics, Inc." have been automatically updated to "Rein Therapeutics, Inc."
- Review the filed Certificate of Amendment (Exhibit 3.1) and Amended and Restated Bylaws (Exhibit 3.2) for any future reference.